Skip to main content
Top
Published in: International Urology and Nephrology 4/2021

01-04-2021 | Diabetic Retinopathy | Nephrology - Original Paper

Non-diabetic glomerular lesions in diabetic kidney disease: clinical predictors and outcome in an Eastern European cohort

Authors: Otilia Popa, Gabriel Stefan, Cristina Capusa, Eugen Mandache, Simona Stancu, Nicoleta Petre, Gabriel Mircescu

Published in: International Urology and Nephrology | Issue 4/2021

Login to get access

Abstract

Purpose

Since patients’ prognosis depends on the lesions identified by kidney biopsy (KB), we aimed to evaluate predictors of non-diabetic kidney disease (NDKD) in diabetic subjects and to assess their kidney outcome as compared to diabetic nephropathy (DN).

Methods

180 adults diagnosed by KB with DN (n = 120) or NDKD (n = 60), over a 10 year time-span, were retrospectively included and followed for a mean of 48.1 (95% CI 43.1–53.1) months. Patients with superimposed specific lesions over DN and with steroid-induced diabetes were excluded. The primary endpoint was renal replacement therapy (RRT) initiation. Only subjects who were alive at the end of follow-up (73 with DN and 38 with NDKD) entered the kidney survival analysis.

Results

Membranous nephropathy (9%) was the most common NDKD. Predictors for NDKD were shorter duration of diabetes (OR 0.88; 95% CI 0.81–0.96, p = 0.004), absence of diabetic retinopathy (OR 0.08; 95% CI 0.01–0.44, p = 0.003), and nephrotic syndrome at presentation (OR 3.55; 95% CI 1.39–9.04, p = 0.008). Subjects with NDKD needed RRT later as those with DN [82 (95% CI 67–97.1) vs. 45 (95% CI 34–56.5) months, p = 0.001]. In an adjusted Cox model, biopsy diagnosed DN independently predicted RRT (OR 4.43; 95% CI 1.54–12.7, p = 0.006). Other predictors were lower eGFR, higher proteinuria, and absence of renin–angiotensin inhibitor therapy.

Conclusion

As one-third of the investigated subjects had NDKD, and NDKD was associated with a better kidney survival, independently predicted by the type of glomerular lesion, KB appears the most reliable tool to guide therapy and to assess outcome in patients with diabetic kidney disease.
Literature
8.
go back to reference Liu MY, Chen XM, Sun XF, Zhou JH, Zhang XG, Zhu HY, Chen YZ, Liu SW, Wei RB, Tang L, Cai GY, Zhang L, Bai XY (2014) Validation of a differential diagnostic model of diabetic nephropathy and non-diabetic renal diseases and the establishment of a new diagnostic model. J Diabetes 6(6):519–526. https://doi.org/10.1111/1753-0407.12150CrossRefPubMed Liu MY, Chen XM, Sun XF, Zhou JH, Zhang XG, Zhu HY, Chen YZ, Liu SW, Wei RB, Tang L, Cai GY, Zhang L, Bai XY (2014) Validation of a differential diagnostic model of diabetic nephropathy and non-diabetic renal diseases and the establishment of a new diagnostic model. J Diabetes 6(6):519–526. https://​doi.​org/​10.​1111/​1753-0407.​12150CrossRefPubMed
14.
go back to reference Hashim Al-Saedi AJ (2009) Pathology of nondiabetic glomerular disease among adult Iraqi patients from a single center. Saudi J Kidney Dis Transpl 20(5):858–861PubMed Hashim Al-Saedi AJ (2009) Pathology of nondiabetic glomerular disease among adult Iraqi patients from a single center. Saudi J Kidney Dis Transpl 20(5):858–861PubMed
23.
go back to reference Zhang PP, Ge YC, Li SJ, Xie HL, Li LS, Liu ZH (2011) Renal biopsy in type 2 diabetes: timing of complications and evaluating of safety in Chinese patients. Nephrology (Carlton) 16:100–105CrossRef Zhang PP, Ge YC, Li SJ, Xie HL, Li LS, Liu ZH (2011) Renal biopsy in type 2 diabetes: timing of complications and evaluating of safety in Chinese patients. Nephrology (Carlton) 16:100–105CrossRef
25.
go back to reference Prakash J (2013) Non-diabetic renal disease (NDRD) in patients with type 2 diabetes mellitus (type 2 DM). J Assoc Physicians India 61(3):194–199PubMed Prakash J (2013) Non-diabetic renal disease (NDRD) in patients with type 2 diabetes mellitus (type 2 DM). J Assoc Physicians India 61(3):194–199PubMed
27.
go back to reference Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ (2012) Relative incidence of ESKD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 59(1):75–83. https://doi.org/10.1053/j.ajkd.2011.09.017CrossRefPubMed Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ (2012) Relative incidence of ESKD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 59(1):75–83. https://​doi.​org/​10.​1053/​j.​ajkd.​2011.​09.​017CrossRefPubMed
Metadata
Title
Non-diabetic glomerular lesions in diabetic kidney disease: clinical predictors and outcome in an Eastern European cohort
Authors
Otilia Popa
Gabriel Stefan
Cristina Capusa
Eugen Mandache
Simona Stancu
Nicoleta Petre
Gabriel Mircescu
Publication date
01-04-2021
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2021
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-020-02681-x

Other articles of this Issue 4/2021

International Urology and Nephrology 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine